4//SEC Filing
DiBiase Mary 4
Accession 0001628280-23-036459
CIK 0001501697other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:55 PM ET
Size
4.9 KB
Accession
0001628280-23-036459
Insider Transaction Report
Form 4
DiBiase Mary
Chief Operating Officer
Transactions
- Award
Common Stock
2023-10-31+230,645→ 378,539 total
Footnotes (1)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001880179
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:55 PM ET
- Size
- 4.9 KB